Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study
assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC
SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0)
NSCLC.

An additional cohort will assess Osimertinib following SBRT in patients with early stage
unresected T1 to T3N0M0 NSCLC harbouring an EGFR mutation.

Treatment Sites in Georgia